Dan is primarily responsible for leading the Biotransformation and Metabolite Identification Team at Sygnature Discovery. Previously, he worked for Schering-Plough in the US, providing biotransformation support for drug discovery. In addition, he held positions at AstraZeneca in the UK, responsible for integrated biotransformation support to respiratory and oncology therapeutic areas, centered upon early de-risking around human safety and metabolic liabilities in late-stage drug development. His research interests include fundamentals of ambient ionization, mass spectrometric imaging and ion-mobility hyphenated with high-resolution mass spectrometry. Dan has a BSc (Hons) in Applied Chemistry and a PhD in ion-trap mass spectrometry, both from Nottingham Trent University, UK.
Sygnature Discovery is a leading independent provider of integrated drug discovery and pre-clinical resource and expertise, offering fully integrated discovery project support, as well as discipline-specific support in medicinal chemistry, computational sciences, bioscience, DMPK or physical sciences as needed by our clients. Sygnature undertake target validation, hit identification, hit-to-lead and lead optimization projects as well as complete drug discovery programs. Since 2011, 30 compounds discovered by Sygnature for clients have entered pre-clinical development and so far, 14 of these have progressed to clinical trials (Phases I, II and III).